---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Effects on other drugs"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Effects on other drugs. Topics: Drug interaction potential of the major metabolite, Drug interaction potential stated by the manufacturer for combination therapy, and Phase 1 interaction study with metformin and paroxetine: research ethics committee record. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Envudeucitinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### Drug interaction potential of the major metabolite

> “Further, in vitro and clinical DDI studies indicate that the major metabolite has minimal potential for DDI interactions.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.9.2-2"></a>

### Drug interaction potential stated by the manufacturer for combination therapy

> “We believe that envu’s pharmacological properties, including its lack of drug-drug interaction potential and its clinical profile, positions it well as a partner for future combination therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.9.2-3"></a>

### Phase 1 interaction study with metformin and paroxetine: research ethics committee record

| Field | Quoted record |
| --- | --- |
| Study title | “Phase 1 Study on impact of ESK-001 PK on Metformin and Paroxetine in Healthy Participants” |
| IRAS ID | “1012125” |
| REC name | “North East - York Research Ethics Committee” |
| REC reference | “25/NE/0105” |
| Date of REC Opinion | “14 Jul 2025” |
| REC opinion | “Further Information Favourable Opinion” |
| Research summary | “Publication of this data is currently deferred.” |

Source: [Health Research Authority research summary, ESK-001 metformin and paroxetine study (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-study-on-impact-of-esk-001-pk-on-metformin-and-paroxetine-in-healthy-participants/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
